Concurrent users
Unlimited
Authorized users
Authorized users
Document Delivery Supplied
Can lend chapters, not whole ebooks
Title
Proteinkinase inhibitors / Stefan Laufer, editor.
ISBN
9783030681807 (electronic bk.)
3030681807 (electronic bk.)
9783030681814 (print)
3030681815
9783030681821 (print)
3030681823
9783030681791
3030681793
Published
Cham, Switzerland : Springer, 2021.
Language
English
Description
1 online resource (vii, 256 pages)
Item Number
10.1007/978-3-030-68180-7 doi
Call Number
QP606.P76
Dewey Decimal Classification
572/.792
615/.798
Summary
This book reviews the principles of design and examples of successful implementation of proteinkinase inhibitors (PKI), and offers a comprehensive and authoritative overview of the history and latest developments in the field. Chapters written by experts from industry and academia cover the function, structure and topology of Proteinkinases, molecular modelling, disclose how to achieve high level of selectivity for kinase inhibitors, and exploit kinase inhibitors for cancer treatment. Particular attention is given to Inhibitors of c-Jun N-terminal kinase 3, and to covalent Janus Kinase 3 Inhibitors. A case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR is also presented in this book. Given its breath, this book will appeal to medicinal chemists, students, researchers and professionals alike.
Bibliography, etc. Note
Includes bibliographical references.
Access Note
Access limited to authorized users.
Digital File Characteristics
text file
PDF
Source of Description
Online resource; title from PDF title page (SpringerLink, viewed April 1, 2021).
Series
Topics in medicinal chemistry (Springer (Firm)) ; v. 36. 1862-2461
Available in Other Form
Print version: 9783030681791
Function, Structure and Topology of Protein Kinases
Molecular Modeling of Protein Kinases: Current Status and Challenges
Covalent Kinase Inhibitors: An Overview
Achieving High Levels of Selectivity for Kinase Inhibitors
Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook
Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR
Inhibitors of c-Jun N-Terminal Kinase 3
Covalent Janus Kinase 3 Inhibitors.